Compare Gartner Inc (IT) vs Pfizer Inc (PFE) Price & Performance

Gartner (IT) trades at $141.06, up 0.62% today, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a net income margin of 11.44% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its leadership in Gartner Magic Quadrant reports, but an ongoing legal investigation adds uncertainty. Cash flow turned negative in 2025 due to high financing outflows, though revenue remains stable around $6.5 billion.

The outlook is cautiously optimistic with a consensus price target of $157.60 suggesting 12% upside. Key opportunities include steady revenue growth and high ROE of 94.88%, but risks involve the legal probe, elevated P/B ratio of 148.08, and volatile cash flows. Investors should weigh strong fundamentals against near-term headwinds.

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.

The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.